Abstract:The WNT/β-catenin is among one of the most extensively studied cellular signaling pathways involved in the initiation and progression of several deadly cancers. It is now understood that the WNT/β-catenin signaling, during tumor progression operates in a very complex fashion beyond the earlier assumed simple WNT 'On' or 'Off' mode as it recruits numerous WNT ligands, receptors, transcriptional factors and also cross-talks with other signaling molecules including the noncanonical WNT regulators. WNT/β-catenin signaling molecules are often mutated in different cancers which makes them very challenging to inhibit and sometimes ranks them among the undruggable targets. Furthermore, due to the evolutionary conservation of this pathway, inhibiting WNT/β-catenin has caused significant toxicity in normal cells. These challenges are reflected in clinical trial data, where the use of WNT/β-catenin inhibitors as standalone treatments remains limited. In this review, we have highlighted the crucial functional associations of diverse WNT/β-catenin signaling regulators with cancer progression and the phenotypic switching of tumor cells. Next, we have shed light on the roles of WNT/β-catenin signaling in drug resistance, clonal evolution, tumor heterogeneity, and immune evasion. The present review also focuses on various classes of routine and novel WNT/β-catenin therapeutic regimes while addressing the challenges associated with targeting the regulators of this complex pathway. In the light of multiple case studies on WNT/β-catenin inhibitors, we also highlighted the challenges and opportunities for future clinical trial strategies involving these treatments. Additionally, we have proposed strategies for future WNT/β-catenin-based drug discovery trials, emphasizing the potential of combination therapies and AI/ML-driven prediction approaches. Overall, here we showcased the opportunities, possibilities, and potentialities of WNT/β-catenin signaling modulatory therapeutic regimes as promising precision cancer medicines for the future.

Effect of Suppressing Tankyrases on Canonical Wnt Pathway: A New Target for the Treatment of Cancer

Targeting Wnt/β-Catenin Pathway for Drug Therapy

Development of Structure-Based Pharmacophore to Target the Β-Catenin-tcf Protein–protein Interaction

Targeting the β-catenin signaling for cancer therapy

Medicinal Chemistry Strategies for the Development of Inhibitors Disrupting β-Catenin's Interactions with Its Nuclear Partners

Wnt/β-catenin Singal Transduction Pathway and Colorectal Cancer

Drug discovery efforts toward inhibitors of canonical Wnt/13-catenin signaling pathway in the treatment of cancer: A composition-of-matter review (2010-2020)

Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex

Targeting the Wnt/β-catenin signaling pathway in cancer

Regulation of Wnt/β-catenin signalling by tankyrase-dependent poly(ADP-ribosyl)ation and scaffolding

Modulating the wnt signaling pathway with small molecules

Inhibition of nuclear Wnt signalling: challenges of an elusive target for cancer therapy

Structure-based discovery of a novel inhibitor targeting the β-catenin/Tcf4 interaction.

Pharmacological interventions in the Wnt pathway: inhibition of Wnt secretion versus disrupting the protein-protein interfaces of nuclear factors

Blocking the WNT/β-catenin pathway in cancer treatment:pharmacological targets and drug therapeutic potential

Distinct CRC-associated APC mutations dictate response to Tankyrase inhibition.

Targeting the Wnt signaling pathway in colorectal cancer

Activating Wnt/β-catenin signaling pathway for disease therapy: Challenges and opportunities

Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy

Belling the "cat": Wnt/β-catenin signaling and its significance in future cancer therapies

Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling.